◎ Sugi Atlas

Atlas / Drug / Everolimus

Everolimus

drug
On this page

Also known as AfinitorAfinitor disperzCerticanRAD 666RAD-001RAD-666RAD001Sdz radSDZ-RADVotubiaZortressSID144206063

Summary

Everolimus (CHEMBL1908360) is an approved small-molecule antineoplastic agent (ATC L01EG02) targeting MTOR; indicated across 147 conditions including breast carcinoma and renal cell carcinoma; with CIViC clinical evidence for 42 variant-indication associations (e.g. TSC1 Loss-of-function in tuberous sclerosis).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01EG02 (+1 more)
  • Targets: 1 (MTOR)
  • Indications: 147 conditions
  • Clinical trials: 712
  • Precision-oncology evidence (CIViC): 42 variant–indication associations
  • Chemistry: 958.2 Da · C53H83NO14

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1908360
NameEverolimus
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID6442177
ChEBICHEBI:68478
ATCL01EG02, L04AH02
Molecular formulaC53H83NO14
Molecular weight958.2
InChIKeyHKVAMNSJSFKALM-GKUWKFKPSA-N

SMILES: C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC

IUPAC name: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone

ChEBI definition: A macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent.

Pharmacological roles (ChEBI): antineoplastic agent, immunosuppressive agent, mTOR inhibitor, anticoronaviral agent, geroprotector.

Also known as: Afinitor, Afinitor disperz, Certican, Everolimus, RAD 666, RAD-001, RAD-666, RAD001, Sdz rad, SDZ-RAD, Votubia, Zortress

Patent coverage: 18,736 distinct patent families (73,430 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
MTORmechanistic target of rapamycin kinaseInhibition8.798.3% (common-essential)P42345

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, Voltage-gated potassium channel, IKs; KCNQ1(Kv7.1)/KCNE1(MinK), Serine/threonine-protein kinase mTOR, mTORC1, ATP-binding cassette sub-family C member 2, ATP-binding cassette sub-family C member 3, Bile salt export pump.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 15 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
MTOR10.3IC500.05nMCHEMBL_ACT_24962479
MTOR10.15IC500.07nMCHEMBL_ACT_25441981
MTOR8.8IC501.6nMCHEMBL_ACT_24788805
MTOR8.7Kd2nMCHEMBL_ACT_18813394
MTOR8.3IC505nMCHEMBL_ACT_20681616
MTOR8.3IC505nMCHEMBL_ACT_24984326
MTOR8.3IC505nMCHEMBL_ACT_25044904
MTOR8.3IC505nMCHEMBL_ACT_29205858
MTOR6.82IC50150nMCHEMBL_ACT_25872954
MTOR6.28IC50530nMCHEMBL_ACT_25683586
ABCB115.7IC502000nMCHEMBL_ACT_18129022

Target pathways

Aggregated over 1 target gene(s): MTOR.

Top Reactome pathways

41 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling1MTOR
Adaptive Immune System1MTOR
Signal Transduction1MTOR
Macroautophagy1MTOR
Disease1MTOR
MTOR signalling1MTOR
mTORC1-mediated signalling1MTOR
Immune System1MTOR
Signaling by VEGF1MTOR
Generic Transcription Pathway1MTOR
PI3K/AKT Signaling in Cancer1MTOR
Cellular responses to stress1MTOR
Cellular response to heat stress1MTOR
HSF1-dependent transactivation1MTOR
Transcriptional Regulation by TP531MTOR
Energy dependent regulation of mTOR by LKB1-AMPK1MTOR
Regulation of T cell activation by CD28 family1MTOR
Co-stimulation by CD281MTOR
CD28 dependent PI3K/Akt signaling1MTOR
VEGFA-VEGFR2 Pathway1MTOR
VEGFR2 mediated vascular permeability1MTOR
TP53 Regulates Metabolic Genes1MTOR
Regulation of TP53 Activity1MTOR
Diseases of signal transduction by growth factor receptors and second messengers1MTOR
Constitutive Signaling by AKT1 E17K in Cancer1MTOR
Regulation of TP53 Degradation1MTOR
Regulation of TP53 Expression and Degradation1MTOR
PTEN Regulation1MTOR
RNA Polymerase II Transcription1MTOR
Gene expression (Transcription)1MTOR

Dominant GO biological processes

GO termTargets
regulation of cell growth1
T-helper 1 cell lineage commitment1
heart morphogenesis1
heart valve morphogenesis1
energy reserve metabolic process1
‘de novo’ pyrimidine nucleobase biosynthetic process1
inflammatory response1
DNA damage response1
cytoskeleton organization1
germ cell development1
regulation of cell size1
cellular response to starvation1
response to heat1
response to virus1
post-embryonic development1

Indications & clinical

Indications

147 indications (21 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
breast carcinoma4MONDO:0004989EFO:0000305
renal cell carcinoma4MONDO:0005086EFO:0000681
neoplasm4MONDO:0005070EFO:0000616
exocrine pancreatic carcinoma4MONDO:0005192EFO:0002618
clear cell renal carcinoma4MONDO:0005005EFO:0000349
lung neuroendocrine neoplasm4MONDO:0005454EFO:0005220
breast neoplasm4MONDO:0021100EFO:0003869
astrocytoma (excluding glioblastoma)4MONDO:0019781EFO:0000272
anaplastic astrocytoma4MONDO:0016684EFO:0002499
pancreatic neoplasm4MONDO:0021040EFO:0003860
pancreatic neuroendocrine tumor4MONDO:0019954EFO:1000045
neuroendocrine neoplasm4MONDO:0019496EFO:1001901
tuberous sclerosis4MONDO:0001734HP:0009720
angiomyolipoma4MONDO:0002603MONDO:0002603
hamartoma4MONDO:0006499EFO:1000634
renal cell adenocarcinoma4MONDO:0005549EFO:0005708
carcinoma3MONDO:0004993EFO:0000313
graft versus host disease3MONDO:0013730EFO:0004599
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
gastric neoplasm3MONDO:0021085EFO:0003897
chronic kidney disease3MONDO:0005300EFO:0003884
cytomegalovirus infection3MONDO:0005132EFO:0001062
coronary restenosis3MONDO:0005355EFO:0004224
carcinoid syndrome3MONDO:0100347EFO:1000852
autosomal dominant polycystic kidney disease3MONDO:0004691EFO:1001496
kidney failure3MONDO:0001106EFO:1002048
kidney cancer3MONDO:0002367MONDO:0002367
skin neoplasm3MONDO:0002531MONDO:0002898
carcinoid tumor3MONDO:0005369MONDO:0024503
coronary artery disorder3MONDO:0005010EFO:0001645
kidney neoplasm3MONDO:0021163EFO:0003865
adenoid cystic carcinoma2MONDO:0004971EFO:0000231
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
mesothelioma2MONDO:0005065EFO:0000588
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
sarcoma2MONDO:0005089EFO:0000691
small cell lung carcinoma2MONDO:0008433EFO:0000702
cholangiocarcinoma2MONDO:0019087EFO:0005221
glioblastoma2MONDO:0018177EFO:0000519
hepatocellular carcinoma2MONDO:0007256EFO:0000182
kidney disorder2MONDO:0005240EFO:0003086
lymphoma2MONDO:0005062EFO:0000574
malignant pleural mesothelioma2MONDO:0005112EFO:0000770
primary cutaneous T-cell non-Hodgkin lymphoma2MONDO:0000607EFO:0002913
germ cell tumor2MONDO:0005040EFO:0000514
lung carcinoma2MONDO:0005138EFO:0001071
central nervous system cancer2MONDO:0002714EFO:0000326
chondrosarcoma2MONDO:0008977EFO:0000333
Hodgkins lymphoma2MONDO:0004952EFO:0000183
osteosarcoma2MONDO:0009807EFO:0000637
hepatitis C virus infection2MONDO:0005231EFO:0003047
acute myeloid leukemia2MONDO:0018874EFO:0000222
brain neoplasm2MONDO:0021211EFO:0003833
Kaposi’s sarcoma2MONDO:0005055EFO:0000558
mantle cell lymphoma2MONDO:0018876EFO:1001469
myelodysplastic syndrome2MONDO:0018881EFO:0000198
age-related macular degeneration2MONDO:0005150EFO:0001365
uveitis2MONDO:0020283EFO:1001231
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
cutaneous melanoma2MONDO:0005012EFO:0000389
epilepsy2MONDO:0005027EFO:0000474
oligoastrocytoma2MONDO:0016702EFO:0000630
oligodendroglioma2MONDO:0016695EFO:0000632
plasma cell myeloma2MONDO:0009693EFO:0001378
metastatic melanoma2MONDO:0005191EFO:0002617
thymus neoplasm2MONDO:0005197EFO:0002626
head and neck cancer2MONDO:0005627EFO:0006859
pancreatic neuroendocrine neoplasm2MONDO:0005815EFO:0007331
transitional cell carcinoma2MONDO:0006474EFO:1000601
marginal zone lymphoma2MONDO:0017604EFO:1000630
soft tissue sarcoma2MONDO:0018078EFO:1001968
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
Waldenstrom macroglobulinemia2MONDO:0100280EFO:0009441
malignant peripheral nerve sheath tumor2MONDO:0017827EFO:0000760
polycystic kidney disease2MONDO:0020642EFO:0008620
diffuse intrinsic pontine glioma2MONDO:0006033EFO:1000026
hyperaldosteronism2MONDO:0003009MONDO:0001422
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
uterine cancer2MONDO:0002715MONDO:0002715
glioma2MONDO:0021042MONDO:0003268
ependymoma2MONDO:0016698MONDO:0003478
gallbladder neoplasm2MONDO:0021253MONDO:0005411
ovarian cancer2MONDO:0008170MONDO:0008170
lung neoplasm2MONDO:0021117MONDO:0008903
endometrium neoplasm2MONDO:0021251MONDO:0011962
colonic neoplasm2MONDO:0005401MONDO:0021063
Peutz-Jeghers syndrome2MONDO:0008280MONDO:0008280
lymphangioleiomyomatosis2MONDO:0011705MONDO:0011705
meningioma2MONDO:0016642MONDO:0016642
tuberculosis2MONDO:0018076MONDO:0018076
neurofibromatosis type 12MONDO:0018975MONDO:0018975
thyroid gland carcinoma2MONDO:0015075EFO:0002892
bile duct carcinoma2MONDO:0005496EFO:0005540
paraganglioma2MONDO:0000448EFO:1000453
uveal melanoma2MONDO:0006486EFO:1000616
colorectal neoplasm2MONDO:0005335MONDO:0005575
Sturge-Weber syndrome2MONDO:0008501MONDO:0008501
acute coronary syndrome1MONDO:0005542EFO:0005672
carcinoma of esophagus1MONDO:0019086EFO:0002916
acute lymphoblastic leukemia1MONDO:0004967EFO:0000220
adenocarcinoma1MONDO:0004970EFO:0000228
chronic myeloid leukemia1MONDO:0011996EFO:0000339
leukemia1MONDO:0005059EFO:0000565
synovial sarcoma1MONDO:0010434EFO:0001376
nasopharyngeal neoplasm1MONDO:0005375EFO:0004252
lymphoid leukemia1MONDO:0005402EFO:0004289
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
male breast carcinoma1MONDO:0005628EFO:0006861
hematologic disorder1MONDO:0005570HP:0001871
central nervous system neoplasm1MONDO:0006130EFO:1000158
peritoneal neoplasm1MONDO:0006901MONDO:0002087
fallopian tube neoplasm1MONDO:0021092MONDO:0002158
progeroid syndrome1MONDO:0015333MONDO:0020732
gastrointestinal stromal tumor1MONDO:0011719MONDO:0011719
Cowden disease1MONDO:0016063MONDO:0017623
plasma cell neoplasm1MONDO:0004959EFO:0000200

31 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 712.

Phase distribution

PhaseTrials
PHASE2265
PHASE1129
PHASE1/PHASE293
PHASE391
PHASE481
Not specified32
PHASE2/PHASE312
EARLY_PHASE19

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02081755PHASE4ENROLLING_BY_INVITATIONSafety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
NCT05252585PHASE4ACTIVE_NOT_RECRUITINGA Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
NCT06584773PHASE4RECRUITINGEfficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients
NCT06942156PHASE4NOT_YET_RECRUITINGOptimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
NCT07426484PHASE4NOT_YET_RECRUITINGCosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
NCT00154297PHASE4COMPLETEDEfficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
NCT00154310PHASE4COMPLETEDEfficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
NCT00170820PHASE4COMPLETEDEfficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen
NCT00170846PHASE4COMPLETEDASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients
NCT00170859PHASE4COMPLETEDEverolimus Versus Mycophenolate Mofetil in Combination With Reduced Dose Cyclosporine Microemulsion in Maintenance Heart Transplant Recipients
NCT00170885PHASE4COMPLETEDEverolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
NCT00332839PHASE4TERMINATEDComparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.
NCT00369161PHASE4COMPLETEDA Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
NCT00371826PHASE4COMPLETEDSOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus
NCT00377962PHASE4COMPLETEDNordic Everolimus (Certican) Trial in Heart and Lung Transplantation
NCT00414440PHASE4COMPLETEDEfficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT00420537PHASE4TERMINATEDShift to Everolimus (RAD) Kidney Sparing Study
NCT00443937PHASE4COMPLETEDPharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients
NCT00505102PHASE4UNKNOWNSafe Renal Function In Long Term Heart Transplanted Patients
NCT00596557PHASE4COMPLETEDEverolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up
NCT00634920PHASE4COMPLETEDEvaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
NCT00695344PHASE4UNKNOWNStudy to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant
NCT00716573PHASE4COMPLETEDEfficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
NCT00862979PHASE4COMPLETEDA Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
NCT00888758PHASE4UNKNOWNComparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction
NCT00903188PHASE4UNKNOWNCalcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
NCT00956293PHASE4TERMINATEDStudy to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program
NCT00965094PHASE4COMPLETEDEfficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
NCT01017029PHASE4COMPLETEDEverolimus in de Novo Heart Transplant Recipients
NCT01046045PHASE4COMPLETEDEverolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients
NCT01169701PHASE4COMPLETED24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients
NCT01183247PHASE4COMPLETEDAn Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens
NCT01206764PHASE4COMPLETEDA Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
NCT01239472PHASE4COMPLETEDCytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
NCT01266148PHASE4COMPLETEDSCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
NCT01266837PHASE4COMPLETEDOpen Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
NCT01269684PHASE4WITHDRAWNImmediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients
NCT01276834PHASE4TERMINATEDComparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation
NCT01312064PHASE4TERMINATEDDe Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction
NCT01317615PHASE4COMPLETEDRAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Clinical evidence (CIViC)

Variant × indication × effect (42 predictive associations from 42 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
TSC1 Loss-of-functionTuberous SclerosisSensitivity/ResponseEverolimusCIViC AEID7280
TSC1 mutation OR TSC2 mutationTuberous SclerosisSensitivity/ResponseEverolimusCIViC AEID11269
TSC2 Loss-of-functionTuberous SclerosisSensitivity/ResponseEverolimusCIViC AEID7281
FGFR1 AmplificationBreast CancerSensitivity/ResponseEndocrine Drug Therapy + EverolimusCIViC BEID12498
KDM5C MutationRenal Cell CarcinomaSensitivity/ResponseSunitinib + EverolimusCIViC BEID5997
NF1 LossMalignant Peripheral Nerve Sheath TumorSensitivity/ResponseEverolimus + BevacizumabCIViC BEID7727
PBRM1 MutationRenal Cell CarcinomaSensitivity/ResponseSunitinib + EverolimusCIViC BEID5996
PIK3CA MutationHer2-receptor Positive Breast CancerSensitivity/ResponseEverolimusCIViC BEID1296
PTEN DeletionProstate CancerSensitivity/ResponseEverolimusCIViC BEID1231
PTEN LossHer2-receptor Positive Breast CancerSensitivity/ResponseEverolimusCIViC BEID1297
PTEN LossCancerSensitivity/ResponseEverolimusCIViC BEID5840
PTEN MutationEndometrial CarcinomaSensitivity/ResponseEverolimusCIViC BEID1232
STK11 F354LBreast CancerSensitivity/ResponseEverolimus + ExemestaneCIViC BEID5568
TSC1 Frameshift TruncationInvasive Bladder Transitional Cell CarcinomaSensitivity/ResponseEverolimusCIViC BEID320
TSC1 Loss-of-functionBladder CarcinomaSensitivity/ResponseEverolimusCIViC BEID155
VHL MutationRenal Cell CarcinomaSensitivity/ResponseEverolimusCIViC BEID5323
BAP1 MutationRenal Cell CarcinomaResistanceEverolimus + SunitinibCIViC BEID5339
PTEN LossBladder CarcinomaResistanceEverolimusCIViC BEID644
AKT2 AmplificationLung AdenocarcinomaSensitivity/ResponseVandetanib + EverolimusCIViC CEID1621
FLCN MutationPapillary Renal Cell CarcinomaSensitivity/ResponseEverolimusCIViC CEID5990
FLCN c.1285dupCRenal Cell CarcinomaSensitivity/ResponseEverolimusCIViC CEID10137
KIF5B::RET FusionLung AdenocarcinomaSensitivity/ResponseEverolimus + VandetanibCIViC CEID1622
MTOR E2014K AND MTOR E2419KTransitional Cell CarcinomaSensitivity/ResponsePazopanib + EverolimusCIViC CEID1438
MTOR MutationBladder CarcinomaSensitivity/ResponseEverolimus + PazopanibCIViC CEID705
PIK3CA H1047RHer2-receptor Positive Breast CancerSensitivity/ResponseEverolimus + FulvestrantCIViC CEID1623
STK11 D194EPancreatic CancerSensitivity/ResponseEverolimusCIViC CEID1617
TSC2 Q1178*Thyroid Gland CarcinomaSensitivity/ResponseEverolimusCIViC CEID1108
MTOR F2108LThyroid Gland CarcinomaResistanceEverolimusCIViC CEID1110
PTEN ExpressionHer2-receptor Positive Breast CancerResistanceEverolimus + FulvestrantCIViC CEID1624
EIF4EBP1 PHOSPHORYLATIONGastric AdenocarcinomaSensitivity/ResponseEverolimusCIViC DEID918

+12 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 8 clinical and 31 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

158 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ALPELISIBChEMBLPhase 4 (approved)MTOR
AMIODARONEChEMBLPhase 4 (approved)MTOR
AMITRIPTYLINEChEMBLPhase 4 (approved)MTOR
AMOXAPINEChEMBLPhase 4 (approved)MTOR
AMSACRINEChEMBLPhase 4 (approved)MTOR
AZACITIDINEChEMBLPhase 4 (approved)MTOR
BROMOCRIPTINEChEMBLPhase 4 (approved)MTOR
CARVEDILOLChEMBLPhase 4 (approved)MTOR
CHLOROQUINEChEMBLPhase 4 (approved)MTOR
CHLORPROMAZINEChEMBLPhase 4 (approved)MTOR
CLEMASTINEChEMBLPhase 4 (approved)MTOR
CLOMIPRAMINEChEMBLPhase 4 (approved)MTOR
COPANLISIBChEMBLPhase 4 (approved)MTOR
CYCLOBENZAPRINEChEMBLPhase 4 (approved)MTOR
CYCLOSPORINEChEMBLPhase 4 (approved)MTOR
CYPROHEPTADINEChEMBLPhase 4 (approved)MTOR
CYTARABINEChEMBLPhase 4 (approved)MTOR
DASATINIBChEMBLPhase 4 (approved)MTOR
DEQUALINIUMChEMBLPhase 4 (approved)MTOR
DESIPRAMINEChEMBLPhase 4 (approved)MTOR
DISULFIRAMChEMBLPhase 4 (approved)MTOR
DOMPERIDONEChEMBLPhase 4 (approved)MTOR
DOPAMINEChEMBLPhase 4 (approved)MTOR
DOXAZOSINChEMBLPhase 4 (approved)MTOR
EBASTINEChEMBLPhase 4 (approved)MTOR
EMETINEChEMBLPhase 4 (approved)MTOR
EPINEPHRINEChEMBLPhase 4 (approved)MTOR
FELODIPINEChEMBLPhase 4 (approved)MTOR
FENOFIBRATEChEMBLPhase 4 (approved)MTOR
FLUOROURACILChEMBLPhase 4 (approved)MTOR
FLUOXETINEChEMBLPhase 4 (approved)MTOR
FLUPHENAZINEChEMBLPhase 4 (approved)MTOR
FLUSPIRILENEChEMBLPhase 4 (approved)MTOR
GUANABENZChEMBLPhase 4 (approved)MTOR
HALOPERIDOLChEMBLPhase 4 (approved)MTOR
HYDROQUINONEChEMBLPhase 4 (approved)MTOR
IDARUBICINChEMBLPhase 4 (approved)MTOR
IMIPRAMINEChEMBLPhase 4 (approved)MTOR
INDOMETHACINChEMBLPhase 4 (approved)MTOR
ISOPROTERENOLChEMBLPhase 4 (approved)MTOR
ISOTRETINOINChEMBLPhase 4 (approved)MTOR
LOPERAMIDEChEMBLPhase 4 (approved)MTOR
LORATADINEChEMBLPhase 4 (approved)MTOR
MAPROTILINEChEMBLPhase 4 (approved)MTOR
MASOPROCOLChEMBLPhase 4 (approved)MTOR
MEMANTINEChEMBLPhase 4 (approved)MTOR
METHYLDOPAChEMBLPhase 4 (approved)MTOR
MIBEFRADILChEMBLPhase 4 (approved)MTOR
MIFEPRISTONEChEMBLPhase 4 (approved)MTOR
MITOXANTRONEChEMBLPhase 4 (approved)MTOR
NAFTOPIDILChEMBLPhase 4 (approved)MTOR
NICARDIPINEChEMBLPhase 4 (approved)MTOR
NICLOSAMIDEChEMBLPhase 4 (approved)MTOR
NIFEDIPINEChEMBLPhase 4 (approved)MTOR
NORTRIPTYLINEChEMBLPhase 4 (approved)MTOR
PACLITAXELChEMBLPhase 4 (approved)MTOR
PANCURONIUMChEMBLPhase 4 (approved)MTOR
PAROXETINEChEMBLPhase 4 (approved)MTOR
PENTAMIDINE ISETHIONATEChEMBLPhase 4 (approved)MTOR
PERPHENAZINEChEMBLPhase 4 (approved)MTOR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot